Adam Clarke

This inventor holds 25 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Cephalon, Inc., Teva Pharmaceuticals Australia Pty Ltd, Cephalon Australia Pty. Ltd.. Active years: 2013-2026.

USPTO Granted Patents = 25 (Patent Applications = 11)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

Five Dock, AU (2013 - 2021)
Sydney, AU (2021)
Riverstone, AU (2023)
Macquarie Park, AU (2014 - 2024)

Company Filing History:

Teva Pharmaceuticals Australia Pty Ltd

patents

2 out of 9

Cephalon Australia Pty. Ltd.

patents

4. 1 out of 1,039

National Research Council of Canada

patents

5. 1 out of 1

Teva Pharmaceuticals Ausralia Pty Ltd

patent

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577298 - Anti-IL-5 Antibodies (2026-03-17),

2. 12410256 - Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases (2025-09-09),

3. 12410247 - Polynucleotides encoding antibodies that specifically bind to human IL-15 (2025-09-09),

4. 12384841 - Anti-PAR-2 antibodies and methods of use thereof (2025-08-12),

5. 12358980 - Compositions and methods for anti-PACAP antibodies (2025-07-15),

6. 12162946 - Antibodies that specifically bind to TL1A and methods of treating gastrointestinal disease (2024-12-10),

7. 12018084 - Anti-CXCR2 antibodies and uses thereof (2024-06-25),

8. 11725052 - Anti-PAR-2 antibodies and methods of use thereof (2023-08-15),

9. 11332534 - Anti-CXCR2 antibodies and uses thereof (2022-05-17),

10. 11319356 - Interferon alpha 2B variants (2022-05-03),

11. 11267883 - Antibodies that specifically bind to human IL-15 and uses thereof (2022-03-08),

12. 11220549 - Antibodies that specifically bind to TL1A and methods of treating respiratory tract diseases (2022-01-11),

13. 11117975 - Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B (2021-09-14),

14. 11111292 - Anti-IL-5 antibodies (2021-09-07),

15. 10981986 - Fusions of antibodies to CD38 and attenuated interferon alpha (2021-04-20),

Title: Inventor Adam Clarke - Revolutionizing Technology in Macquarie Park, AU

Introduction: Adam Clarke is a visionary inventor based in Macquarie Park, AU, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Adam Clarke holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Adam Clarke has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Adam Clarke has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and creativity in all his projects.

Conclusion: Adam Clarke's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs in Macquarie Park, AU, and beyond.